Join Growin Stock Community!

Viatris inc.VTRS.US Overview

US StockHealthcare
(No presentation for VTRS)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

VTRS AI Insights

VTRS Overall Performance

VTRS AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

VTRS Recent Performance

-0.27%

Viatris inc.

0.05%

Avg of Sector

-0.31%

S&P500

VTRS PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

VTRS Key Information

VTRS Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

VTRS Profile

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Price of VTRS

VTRS FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

VTRS Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.05
PE Ratio (TTM)
-
Forward PE
6.49
PS Ratio (TTM)
1.21
PB Ratio
1.16
Price-to-FCF
9.17
METRIC
VALUE
vs. INDUSTRY
Gross Margin
35.06%
Net Margin
-24.58%
Revenue Growth (YoY)
-2.98%
Profit Growth (YoY)
-10.85%
3-Year Revenue Growth
-1.51%
3-Year Profit Growth
-3.42%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.05
PE Ratio (TTM)
-
Forward PE
6.49
PS Ratio (TTM)
1.21
PB Ratio
1.16
Price-to-FCF
9.17
Gross Margin
35.06%
Net Margin
-24.58%
Revenue Growth (YoY)
-2.98%
Profit Growth (YoY)
-10.85%
3-Year Revenue Growth
-1.51%
3-Year Profit Growth
-3.42%

  • When is VTRS's latest earnings report released?

    The most recent financial report for Viatris inc. (VTRS) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating VTRS's short-term business performance and financial health. For the latest updates on VTRS's earnings releases, visit this page regularly.

  • What is the operating profit of VTRS?

    According to the latest financial report, Viatris inc. (VTRS) reported an Operating Profit of -192.7M with an Operating Margin of -5.2% this period, representing a decline of 7.17% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is VTRS's revenue growth?

    In the latest financial report, Viatris inc. (VTRS) announced revenue of 3.7B, with a Year-Over-Year growth rate of 4.97%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does VTRS have?

    As of the end of the reporting period, Viatris inc. (VTRS) had total debt of 14.41B, with a debt ratio of 0.39. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does VTRS have?

    At the end of the period, Viatris inc. (VTRS) held Total Cash and Cash Equivalents of 1.32B, accounting for 0.04 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does VTRS go with three margins increasing?

    In the latest report, Viatris inc. (VTRS) did not achieve the “three margins increasing” benchmark, with a gross margin of 31%%, operating margin of -5.2%%, and net margin of -9.2%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess VTRS's profit trajectory and future growth potential.

  • Is VTRS's EPS continuing to grow?

    According to the past four quarterly reports, Viatris inc. (VTRS)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.3. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of VTRS?

    Viatris inc. (VTRS)'s Free Cash Flow (FCF) for the period is 640.5M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 86.84% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.